PPRS overhaul to focus on value to patients and NHS

摘要

Renegotiation of the pharmaceutical price regulation scheme(PPRS)will focus on delivering value to the NHS,to patients and to the taxpayer,the Government has said.Publishing its interim response to the Office of Pair Trading's market study on the current PPRS(PJ,24 February,p208),the Government announced its intention to overhaul the scheme.Four aims will guide the renegotiation:delivering value for money;rewarding and encouraging innovation;assisting the uptake of new medicines;and providing stability,sustainability and predictability.Stephen Timms,minister for competition,said:"We are undertaking a continuing programme of detailed analysis of the OFT report's proposals,and will discuss this analysis with the industry,taking into account their strong concerns about a number of the proposals....We will take this work forward over the coming months and will discuss proposals with industry.We will then aim to make further proposals as part of the renegotiation of the PPRS."